NASDAQ:TMDX - TransMedics Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.50
  • Forecasted Upside: 9.35 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$33.38
▼ -1.78 (-5.06%)

This chart shows the closing price for TMDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TransMedics Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMDX

Analyst Price Target is $36.50
▲ +9.35% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $36.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 9.35% upside from the last price of $33.38.

This chart shows the closing price for TMDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in TransMedics Group. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/29/2022Morgan StanleyBoost Price TargetEqual Weight$25.00 ➝ $34.00Low
6/28/2022CowenBoost Price TargetOutperform$35.00 ➝ $39.00Low
5/4/2022Canaccord Genuity GroupBoost Price Target$39.00 ➝ $46.00High
5/4/2022CowenBoost Price Target$28.00 ➝ $35.00High
3/17/2022Canaccord Genuity GroupBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.00High
3/17/2022Canaccord Genuity GroupBoost Price TargetBuy$38.00 ➝ $39.00High
2/25/2022Morgan StanleyLower Price TargetEqual Weight$22.00 ➝ $15.00High
2/25/2022Canaccord Genuity GroupLower Price Target$79.00 ➝ $38.00High
2/24/2022JPMorgan Chase & Co.Lower Price Target$20.00 ➝ $12.00High
1/7/2022Morgan StanleyLower Price TargetEqual Weight$33.00 ➝ $22.00High
10/14/2021JPMorgan Chase & Co.Boost Price TargetNeutral$29.00 ➝ $30.00Low
10/8/2021CowenLower Price TargetOutperform$49.00 ➝ $39.00High
7/8/2021OppenheimerInitiated CoverageBuy$49.00Medium
6/18/2021CowenReiterated RatingBuy$49.00High
5/5/2021Morgan StanleyLower Price TargetEqual Weight$38.00 ➝ $35.00High
3/29/2021CowenBoost Price TargetPositive ➝ Outperform$44.00 ➝ $49.00Low
3/3/2021Morgan StanleyBoost Price TargetEqual Weight$16.00 ➝ $38.00High
3/2/2021OppenheimerBoost Price TargetHold ➝ Outperform$25.00 ➝ $40.00High
2/24/2021CowenBoost Price TargetOutperform$20.00 ➝ $44.00High
11/6/2020Morgan StanleyLower Price TargetEqual Weight$18.00 ➝ $16.00Low
11/5/2020OppenheimerReiterated RatingBuy$25.00High
10/8/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$15.00Low
8/7/2020Morgan StanleyBoost Price TargetEqual Weight$15.00 ➝ $18.00Medium
8/6/2020OppenheimerReiterated RatingBuy$25.00High
7/1/2020OppenheimerInitiated CoverageBuy$25.00Low
5/6/2020OppenheimerReiterated RatingBuy$25.00High
4/19/2020OppenheimerInitiated CoverageOutperform$25.00Medium
4/6/2020OppenheimerInitiated CoverageOutperform$25.00High
3/4/2020Morgan StanleyLower Price TargetEqual Weight$22.00 ➝ $16.00Medium
11/7/2019CowenLower Price TargetOutperform$40.00 ➝ $28.00High
5/28/2019Morgan StanleyInitiated CoverageEqual ➝ Equal WeightHigh
5/28/2019JPMorgan Chase & Co.Initiated CoverageOverweight$34.00High
5/28/2019CowenInitiated CoverageOutperform ➝ Outperform$40.00High
(Data available from 7/7/2017 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
12/9/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/8/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
3/9/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
5/8/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022

Current Sentiment

  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Today's Range

Now: $33.38
Low: $33.07
High: $35.38

50 Day Range

MA: $28.11
Low: $20.96
High: $35.16

52 Week Range

Now: $33.38
Low: $10.00
High: $35.38

Volume

240,017 shs

Average Volume

244,045 shs

Market Capitalization

$933.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of TransMedics Group?

The following Wall Street research analysts have issued stock ratings on TransMedics Group in the last year: Canaccord Genuity Group Inc., Cowen Inc, JPMorgan Chase & Co., Morgan Stanley, and Oppenheimer Holdings Inc..
View the latest analyst ratings for TMDX.

What is the current price target for TransMedics Group?

0 Wall Street analysts have set twelve-month price targets for TransMedics Group in the last year. Their average twelve-month price target is $36.50, suggesting a possible upside of 9.3%.
View the latest price targets for TMDX.

What is the current consensus analyst rating for TransMedics Group?

TransMedics Group currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TMDX will outperform the market and that investors should add to their positions of TransMedics Group.
View the latest ratings for TMDX.

What other companies compete with TransMedics Group?

How do I contact TransMedics Group's investor relations team?

TransMedics Group's physical mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company's listed phone number is (978) 552-0900 and its investor relations email address is [email protected] The official website for TransMedics Group is www.transmedics.com. Learn More about contacing TransMedics Group investor relations.